GlobeNewswire by notified

Conagen Successfully Develops Antioxidant Kaempferol by Precision Fermentation

Share

Bedford, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Conagen, the Massachusetts-based biotechnology innovator, announced the successful development of antioxidant kaempferol produced by state-of-the-art, proprietary, precision fermentation. As a biotechnology company specializing in developing commercially valuable molecules for its partners and clients, Conagen’s kaempferol enables brands in nutrition, beauty, and personal care products to adopt a more natural position by formulating with clean and sustainable kaempferol.

Recognized as one of nature’s most potent antioxidants, kaempferol is a flavonoid with health-promoting properties found in tea, fruits, and vegetables, especially rich in green leafy vegetables such as spinach and kale.

Rising consumer awareness towards chronic diseases such as cancer and diabetes drives the kaempferol market demand. The global kaempferol market may exceed $6.5 billion by 2025, according to a recent research report by Global Market Insights, Inc.

“We’re bringing to market a pure and natural kaempferol at affordable prices that were not possible or available until now,” said Casey Lippmeier, Ph.D. vice president of innovation at Conagen. “Conagen’s scalable, precision fermentation for producing flavonoids like kaempferol is more efficient and sustainable than what can be achieved with the chemically-synthesized or botanically-sourced molecule." 

Flavonoids are polyphenolic compounds commonly found in plants and are a significant part of the human diet. They are biosynthesized by plants and fungi as secondary metabolites and comprise a diverse group of phytonutrients.

Plants protect themselves and their fruits against biological intruders such as fungi and bacteria by using phenolic phytochemicals, including flavonoids. Accordingly, kaempferol provides powerful anti-microbial, anti-inflammatory, and immune system benefits to humans.

Dietary kaempferol in multiple studies has demonstrated a wide range of promising beneficial activities, primarily as an anti-inflammatory and antioxidant, for reducing the risk of chronic diseases, especially cancer.

Prolonged oxidative stress leads to premature aging and can trigger many degenerative diseases and cancer. Kaempferol’s powerful antioxidant property can help the body’s defense against free radicals that promote cancer development.

Conagen derived kaempferol from its molecular platform for flavonoid antioxidants, including the previously announced molecules: DHQ, also known as Taxifolin, p-coumaric acid, hydroxytyrosol, and rosmarinic acid. The development of natural kaempferol is good news for Conagen’s commercialization partner, Blue California, as kaempferol will expand its offerings of specialty ingredient solutions.

"This launch further demonstrates our talent for delivering innovative compounds which are ideal for dietary supplements and ‘clean-label’ ingredients for functional foods, beverages, and cosmetics," said Lippmeier. “Our vision for promoting health and wellness is to continuously leverage our precision fermentation capabilities for high-quality phenolic and flavonoid phytonutrients, thus confirming our position as a leader in the development of strains and processes for making clean-label ingredients and nutraceuticals."

Blue California has a long-standing partnership with biotechnology innovator Conagen. Conagen focuses on developing sustainable, nature-based ingredients that improve existing options in the market or represent completely novel ingredient solutions.

###

About Conagen

Conagen is a product-focused, synthetic biology R&D company with large-scale contract manufacturing capabilities. Our scientists and engineers use the latest synthetic biology tools to develop high-quality, sustainable, nature-based products by precision fermentation and enzymatic bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceutical, and renewable materials industries. www.conagen.com

About Blue California

Blue California is a vertically integrated technology company providing innovative ingredient solutions to global partners. With more than 20 years of innovation success, our ingredients are used in commercial products and applications in nutrition, personal care, healthy aging and wellness, functional food and beverage, and beauty. www.bluecal-ingredients.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Benevity’s 2024 Corporate Goodness Awards Celebrate Groundbreakers in Social Impact26.4.2024 13:00:00 CEST | Press release

Awards recognize purpose-driven brands for their extraordinary approaches to social impact, corporate philanthropy and employee engagement PALM SPRINGS, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Benevity Inc., the leading global provider of social impact software, today announced the winners of its 2024 Corporate Goodness Awards, also known as “The Goodies,” acknowledging leading-edge brands for their innovative and inspirational approaches to social impact, employee engagement and corporate philanthropy. The 2024 Goodie Awards were presented to the winners on April 25 in Palm Springs, CA at Benevity Live!, the company’s flagship conference, which brings together more than 700 purpose-driven professionals to share insights and strategies about the future of corporate impact. This year saw a record-breaking 197 nominations from 99 of the world’s most iconic and purpose-driven brands. The winners were recognized across various categories based on the innovative, inclusive and creative w

NGS Group AB: Offentliggör årsredovisning 202326.4.2024 13:00:00 CEST | Pressemelding

Härmed offentliggör NGS Group AB (publ) sin årsredovisning för 2023. Årsredovisningen finns även tillgänglig på bolagets hemsida www.ngsgroup.se. För ytterligare information kontakta: Thomas Plate, CFO för NGS Group på telefon 076-894 9239 eller mailadress thomas.plate@ngsgroup.se. Denna information är sådan som NGS Group AB (publ) är skyldig att offentliggöra enligt lagen om värdepappersmarknaden, lagen om handel med finansiella instrument samt Nasdaq Stockholms regelverk. Informationen lämnades för offentliggörande den 26 april 2024. Bilagor Årsredovisning 2023 - NGS Group AB (publ)ngsgroupab-2023-12-31-sv

Digitalist Group Plc - Managers' Transactions26.4.2024 13:00:00 CEST | Press release

Digitalist Group Plc Managers’ transactions 26 April 2024 at 14:00 Digitalist Group Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Turret Oy Ab Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Paul Ehrnrooth Position: Member of the Board (2):Person Discharging Managerial Responsibilities In Issuer Name: Peter Eriksson Position: Member of the Board Issuer: Digitalist Group Oyj LEI: 743700AL68PUX6JMS644 Notification type: INITIAL NOTIFICATION Reference number: 59985/5/6 ____________________________________________ Transaction date: 2024-04-26 Venue: OFF-EXCHANGE LIIKETOIMET (XOFF) Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of the instrument: igitalist Group Oyj:n Vaihtovelkakirjalaina 2021/1 Nature of transaction: SUBSCRIPTION Transaction details (1): Volume: 65000000 Unit price: 0 N/A Aggregated tran

Forløb af ordinær generalforsamling i ØK - Selskabsmeddelelse nr. 4/202426.4.2024 12:57:02 CEST | pressemeddelelse

26. april 2024 Den 26. april 2024 kl. 11.00 afholdtes ordinær generalforsamling i Det Østasiatiske kompagni A/S, i Asia House, Indiakaj 16, 2100 København Ø. På den ordinære generalforsamling blev følgende dagsordenspunkter behandlet: a. Bestyrelsens beretning blev taget til efterretning. b. Årsrapporten for 2023 blev godkendt. c. Der blev meddelt decharge for bestyrelsen og direktionen. d. Anvendelse af årets resultat i overensstemmelse med den godkendte årsrapport blev godkendt. e. Præsentation af vederlagsrapporten for 2023. f. Bestyrelsens honorar for 2024 blev vedtaget. g. Ole Steffensen, Martin Thaysen og Kresten M. Valdal blev valgt som medlemmer til bestyrelsen. h. KPMG P/S blev genvalgt som selskabets revisor. i. Bestyrelsen bemyndigedes til at lade selskabet erhverve egne aktier. j. Forslag fra bestyrelsen om: Selskabets vederlagspolitik blev godkendt.Forslaget om ændring af selskabets navn til ”Det Østasiatiske Kompagni A/S” og optagelse af binavne blev vedtaget. k. Dirigent

Resolutions of Harvia Plc's Annual General Meeting on 26 April 202426.4.2024 12:30:00 CEST | Press release

STOCK EXCHANGE RELEASE 26 April 2024 at 1.30 p.m. EEST Resolutions of Harvia Plc's Annual General Meeting on 26 April 2024 Harvia Plc’s Annual General Meeting, held today on 26 April 2024, approved the financial statements and discharged the members of the Board of Directors and the company’s CEO from liability for the financial year 2023. The Annual General Meeting approved in an advisory decision the remuneration report for governing bodies. The Annual General Meeting resolved to reject the revised remuneration policy for the company’s governing bodies. The resolution made is advisory. Use of the profit shown on the balance sheet and the distribution of dividend The Annual General Meeting approved the Board of Directors’ proposal that EUR 0.68 per share be paid as dividend and that the remainder of the distributable funds be transferred to shareholders’ equity. The dividend is paid in two instalments. The first instalment, EUR 0.34 per share, will be paid to shareholders who are regi

HiddenA line styled icon from Orion Icon Library.Eye